Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anerest is a pharmaceutical product developed and marketed by MetaneX Life Science, containing the active ingredient etizolam. Etizolam is a thienodiazepine derivative that functions as a potent anxiolytic, sedative-hypnotic, and skeletal muscle relaxant. Its mechanism of action involves the positive allosteric modulation of the gamma-aminobutyric acid type A (GABA-A) receptor complex. By binding to the regulatory site of the receptor, it enhances the inhibitory effects of the neurotransmitter GABA, leading to reduced neuronal excitability throughout the central nervous system. Anerest is primarily indicated for the short-term management of anxiety disorders, panic disorders, and insomnia. As a generic product from an Indian manufacturer, it is positioned within the psychiatric and neurological segment of their product portfolio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Anerest.